Olanzapine-d8 |
| Catalog No.GC40225 |
Olanzapine-d8 is intended for use as an internal standard for the quantification of olanzapine by GC- or LC-MS.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1093380-13-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Olanzapine-d8 is intended for use as an internal standard for the quantification of olanzapine by GC- or LC-MS. Olanzapine is an atypical antipsychotic that binds to dopamine D1, D2, and D4 receptors (Kis = 31, 11, and 27 nM, respectively) as well as the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2C, and 5-HT3 (Kis = 4, 11, and 57 nM, respectively). It also binds to M1 muscarinic acetylcholine, α1-adrenergic, and histamine H1 receptors (Kis = 2, 19, and 7 nM, respectively).[1] Olanzapine (0.5 mg/kg, i.p.) decreases immobility time in the forced swim test in non-stressed and prenatally-stressed rats, indicating antidepressant-like activity. [2]It also decreases the number of avoidances made in the conditioned avoidance response test in rats when administered at doses of 0.5 and 1 mg/kg. [3] Formulations containing olanzapine have been used in the treatment of schizophrenia and bipolar disorder.
Reference:
[1]. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2), 87-96 (1996).
[2]. Nowakowska, E., Kus, K., Ratajczak, P., et al. The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats. Pharmacol. Rep. 66(3), 404-411 (2014).
[3]. Ashby, D.M., Lapish, C.C., and Phillips, A.G. Stability of avoidance behaviour following repeated intermittent treatment with clozapine, olanzapine or D,L-govadine. Behav. Pharmacol. 26(1-2), 133-138 (2015).
| Cas No. | 1093380-13-2 | SDF | |
| Chemical Name | 2-methyl-4-(4-methyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)-10H-thieno[2,3-b][1,5]benzodiazepine | ||
| Canonical SMILES | CN(C([2H])([2H])C1([2H])[2H])C([2H])([2H])C([2H])([2H])N1C2=NC3=CC=CC=C3NC4=C2C=C(C)S4 | ||
| Formula | C17H12D8N4S | M.Wt | 320.5 |
| Solubility | 16 mg/ml in DMSO, 20 mg/ml in DMF, 1 mg/ml in Ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1201 mL | 15.6006 mL | 31.2012 mL |
| 5 mM | 0.624 mL | 3.1201 mL | 6.2402 mL |
| 10 mM | 0.312 mL | 1.5601 mL | 3.1201 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *